Fatty liver: MASLD, a common disease to detect early

· 5 min read · Dr Youssef BENNANI

Plate of healthy food, the foundation of fatty liver management

Non-alcoholic fatty liver disease has a new name: MASLD. The European liver, diabetes and obesity societies have issued joint guidelines to improve its detection and treatment. Here is what you need to know.

Why a new name?

In 2023, the major liver societies (European, American and Latin American) adopted a new nomenclature. Non-alcoholic fatty liver disease (NAFLD) becomes MASLD, for Metabolic dysfunction-Associated Steatotic Liver Disease. Its inflammatory form, formerly called NASH, becomes MASH.

It is more than a new word: diagnosis now relies on positive criteria, not only on the absence of alcohol use.

What is MASLD?

MASLD means there is excess fat in the liver (steatosis) together with at least one cardiometabolic risk factor:

  • overweight or a large waist circumference;
  • high blood sugar or type 2 diabetes;
  • high blood pressure;
  • high triglycerides or low "good" cholesterol (HDL).

It is the most common liver disease, affecting nearly one adult in three worldwide. Usually silent, it can progress in some patients to fibrosis, cirrhosis and liver cancer.

What the 2024 European guidelines say

Published in 2024 in the Journal of Hepatology by EASL, EASD and EASO, they stress three points:

  • look for the disease in people at risk: type 2 diabetes, obesity with another metabolic factor, abnormal liver tests or steatosis found on ultrasound;
  • assess fibrosis step by step, without a biopsy in most cases: a score calculated from a simple blood test (FIB-4), then liver elastography if needed;
  • change lifestyle first, and treat diabetes, blood pressure and cholesterol.

How to protect your liver

  • lose weight if you are overweight: losing about 5% reduces liver fat, and losing 7 to 10% or more improves inflammation and fibrosis;
  • follow a Mediterranean-style diet: vegetables, fruit, legumes, fish, olive oil, little added sugar and few sugary drinks (see our dietary advice);
  • get regular physical activity, even moderate;
  • avoid alcohol, which worsens liver damage.

Specific medicines are starting to be approved in some countries for forms with fibrosis. Whether they are appropriate is a specialist decision. To learn more about liver diseases, see our Hepatology page.

Frequently asked questions

Does MASLD only affect overweight people?

No. It is more common in people who are overweight or have diabetes, but it also occurs in people of normal weight who have another metabolic factor (blood pressure, cholesterol, blood sugar).

The disease often causes no symptoms. It is found on an ultrasound or a blood test. If you are at risk, talk to your doctor, who can assess your liver.

Yes, steatosis can regress with weight loss, a balanced diet and physical activity. The earlier it is managed, the better the results.

Rarely. Guidelines favor non-invasive tests: a blood-based score, then elastography. Biopsy is reserved for cases where the diagnosis remains uncertain.

Sources

  1. EASL–EASD–EASO — Clinical Practice Guidelines on the management of MASLD, Journal of Hepatology 2024 (PubMed 38851997)
  2. Summary of the EASL–EASD–EASO guidelines, Diabetologia 2024
  3. Rinella ME et al. — A multisociety Delphi consensus statement on new fatty liver disease nomenclature, Journal of Hepatology 2023
Informational article written by Dr Youssef Bennani. It does not replace a consultation: if you have symptoms, see a doctor.
Directions